Default Theme

अखिल भारतीय आयुर्विज्ञान संस्थान, नई दिल्ली
All India Institute Of Medical Sciences, New Delhi

OPD Appointment

AIIMS Dashboard

ORBO Donor Pledge Form

Swasth Nari, Sashakt Parivar Abhiyaan Health Campaign

Information about Body donation Program & Will form for Body donation

Patient Care Services

Amar Ranjan Singh

Details: Last Updated on Thursday, 08 October 2026 11:32

Name: Dr. Amar Ranjan Singh

Sex (M/F): M

Date of Birth: 04/10/1969

Designation: Professor

Department: Onco-Haematopathology, Dr. B. R. A.-I.R.C.H

Institute/University: All India Institute of Medical Sciences, Ansari Nagar, New Delhi, PIN: 110029

Education (Post-Graduation & Professional Career)

S.No.	Institution / Place	Degree	Year	Field of Study
1	Patna Medical College, Patna	MD (Pathology)	1999–2002	Histopathology, Cytopathology, Hematology, Blood Banking & UG Teaching

Position and Honors

Research Projects - Principal Investigator

S.No.	Title	Duration / Date	Funding Agency	Budget (Lakh)	Status / ID
1	Evaluation of Thrombopoietin as a marker of sepsis in post operative cases of gastrointestinal malignancy	09/09/2015 To 08/09/2016	AIIMS, New Delhi	4.0	Completed (A-348)
2	Evaluation of HE4 level in epithelial ovarian cancer for diagnosis & monitoring of therapy	01.08.2017 To 31.07.2022	ICMR, New Delhi	40.0	Completed (I-971)
3	Prognostic evaluation of thrombopoietin following surgery in gastrointestinal cancer patients	06.09.2018 To 05.09.2019	Oncology Forum, New Delhi	1.5	Completed (N01896)
4	Analysis of expression of biomarkers in ovarian cancer	26.08.2019 To 25.08.2021	AIIMS, New Delhi	10.0	Ongoing (A-698)
5	Clinicopathological correlation of Mantle cell lymphoma, single center study	09.03.2021	Non-funded project	—	—
6	Establishment of diagnostic scoring system for Plasmablastic lymphoma	25.09.2021	Non-funded project	—	—

MBBS Mentorship Program (AIIMS, Delhi)

1. To evaluate the role of thrombopoietin as a biomarker for sepsis in post-operative cases of thoraco-abdominal surgery

Candidates: Mr. Saransh Verma & Mr. Abdur Rehman Asrarul Haque
Date: 17.08.2022 (One-year scheme, UG-45)

2. Clinical evaluation of IEX1 & FOXJ1 gene expression in ovarian cancer

Candidates: Mr. Jitendra Yadav & Mr. Raghaven Khandal
Date: 25.05.2022 (One-year scheme, UG-43)

Book Chapters

Dubey H, Modi M, Ranjan A, et al. Tissue engineering: methods for scaffolds to extracellular matrix and scaffold to cell interaction. In: Verma Y, Mukharjee M, Kumar S, Kumar S, editors. Fundamentals of Translational Tissue Engineering. Academic Press (Elsevier); Sept. 2026.
Balaji D, Panga SK, Dubey H, Anandani G, Merla SV, Anupurba S, Modi M, Bhankhodia V, Sharma A, Ranjan A, Yadav A, Kumari N, Singh G, Mittal GS. Recent Advances in Forensic Toxicology. In: Medical Science: Recent Advances and Applications, Vol. 4, Chapter 9. BP International Publishers; May 10, 2025. Print ISBN: 978-93-49970-32-8, eBook ISBN: 978-93-49729-88-9; DOI: https://doi.org/10.9734/bpi/msraa/v4/5451
Panga SK, Balaji D, Dubey H, Dwivedi S, Yadav A, Rathod GB, Singh G, Ranjan A, Anupurba S, Sharma A, Anandani G, Mittal GS. Recent Advances in Forensic Medicine: An Overview. In: Medical Science: Recent Advances and Applications, Vol. 3. BP International Publisher; May 2, 2025. DOI: https://doi.org/10.9734/bpi/msraa/v3/5394
Dubey H, Gupta S, Kumar A, Goel H, Merla SV, Menda J, Bharti G, Ranjan A, Kumari R, Dubey N, Chopra A, Tanwar P, Kumar A. Genetic and Molecular Analysis of Cancer Testis Antigen 45 in Ovarian Cancer: A Review. Accepted book chapter, BP International, manuscript number 2025/BPR/4537; April 2024.
Aggarwal J, Ranjan A, Midha U, Dubey H, Dutta R, Gupta S. Oxidative Stress in Breast Cancer. In: Perspective of Recent Advances in Medical Science, Vol. 4, Chapter 5. Print ISBN: 978-81-961090-4-2, eBook ISBN: 978-81-961090-0-4; DOI: 10.9734/bpi/pramr/v4/4047B. Available from: https://www.bookpi.org/bookstore/product/perspective-of-recent-advances-in-medical-research-vol-4/
Aggarwal J, Ranjan A, Khan MA, Dubey H, Midha U, Dutta R. Recent Advances in the Management of Neurological Disorders: Raising Hopes and Future Challenges. In: Perspective of Recent Advances in Medical Research, Vol. 3, Chapter 4. Print ISBN: 978-81-960791-8-5, eBook ISBN: 978-81-960791-3-0; DOI: 10.9734/bpi/pramr/v3/4024B. Available from: https://www.bookpi.org/bookstore/product/perspective-of-recent-advances-in-medical-research-vol-3/
Dubey H, Modi M, Verma S, Sinha R, Goel H, Ranjan A, Tanwar P, Chopra A, Rahul E, Ranjan L, Verma N. Role of Human Epididymis Protein 4 in Tumour Angiogenesis. In: Recent Advances, New Perspectives and Applications in the Treatment of Ovarian Cancer. IntechOpen; July 8, 2022. DOI: 10.5772/intechopen.105678
Mahto KK, Prasad P, Kumar M, Dubey H, Ranjan A. Role of CRISPR Technology in Gene Editing of Emerging and Re-emerging Vector Borne Disease. In: Puerta-Guardo H, Manrique-Saide P, editors. Mosquito Research - Recent Advances in Pathogen Interactions, Immunity, and Vector Control Strategies. London: IntechOpen; 2022. Available from: https://www.intechopen.com/online-first/81476; DOI: 10.5772/intechopen.104100
Ranjan A, Dubey H, Pramanik R, Sethi D, Tanwar P, Ranjan L, Chandrashekhara SH, Wadhwani M. Determination of Lymphoma without Peripheral Lymphadenopathy: An Approach to Definitive Diagnosis by Flowcytometry. Issues and Developments in Medicine and Medical Research, Vol. 6; February 4, 2022, pp. 131–143.
Ranjan A, Rizwan A, Ranjan L, Dubey H, Ray MD. Research and Publication: Importance in the 21st Century. In: Multidisciplinary Approach to Surgical Oncology Patients. Springer, Singapore; 2021, pp. 143–149.

(Ten best publications in chronological order)

Goel H, Pandey AK, Kumar R, Kumar R, Ningombam SS, Naz F, Makkar H, Singh J, Ali S, Chopra A, Ranjan A, Gupta AK, Meena JP, Viswanathan GK, Bakhshi S, Sahoo RK, Batra A, Rath GK, Hussain S, Jha AK, Tanwar P. RNA Sequencing Identifies WT1 Overexpression as a Predictor of Poor Outcomes in Acute Myeloid Leukemia. Cancers (Basel). 2025 May 29;17(11):1818. doi: 10.3390/cancers17111818. PMID: 40507300; PMCID: PMC12153777.
Naz F, Tanveer N, Verma H, Arava S, Kakkar A, Pandey S, Goel H, Ranjan A, Chopra A, Tanwar P. Histomorphology based prediction of p16 immunopositivity and p16/HPV DNA co-positivity in oral squamous cell carcinoma. Ann Diagn Pathol. 2024 Dec;73:152389. doi: 10.1016/j.anndiagpath.2024.152389. Epub 2024 Oct 24. PMID: 39481322.
Naz F, Tanveer N, Verma H, Sudheer KA, Kakkar A, Ranjan A, Chopra A, Tanwar P. Relevance of Partial p16 Immunostaining in Oral Squamous Cell Carcinoma and Co-Relation with HPV DNA Status. Asian Pac J Cancer Prev. 2023 Dec 1;24(12):4093-4096. doi: 10.31557/APJCP.2023.24.12.4093. IF 2.54
Rawal N, Awasthi S, Dash NR, Kumar S, Das P, Ranjan A, Chopra A, Khan MA, Saluja S, Hussain S, Tanwar P. Prognostic Relevance of PDL1 and CA19-9 Expression in Gallbladder Cancer vs. Inflammatory Lesions. Current Oncology. 2023 Jan 25;30(2):1571-84.
Kumar R, Kumar R, Goel H, Kumar S, Ningombam SS, Haider I, Agrawal U, Deo S, Gogia A, Batra A, Sharma A, Mathur S, Ranjan A, Chopra A, Hussain S, Tanwar P. Whole exome sequencing identifies novel variants of PIK3CA and validation of hotspot mutation by droplet digital PCR in breast cancer among Indian population. Cancer Cell Int. 2023 Oct 11;23(1):236.
Ningombam A, Verma D, Kumar R, Singh J, Ali MS, Pandey AK, Singh I, Bakhshi S, Sharma A, Pushpam D, Palanichamy JK, Tanwar P, Singh AR, Chopra A. Prognostic relevance of NPM1, CEBPA, and FLT3 mutations in cytogenetically normal adult AML patients. Am J Blood Res. 2023 Feb 15;13(1):28-43.
Dubey H, Ranjan A, Jain G, Kumar C, Batra A, Chellapuram SK, Gupta S, Goel H, Sharma A, Tanwar P. Bone marrow metastasis of testicular germ cell tumour: A rare case. Heliyon. 2023 May 29. I.F. 3.776, Online ISSN: 2405-8440.
Verma S, Dubey H, Gupta S, Ranjan A*, Goel H, Sharma A. Neuroendocrine carcinoma of cervix and review literature. Int J Surg Case Rep. 2023 Apr;105:107982. doi: 10.1016/j.ijscr.2023.107982. Epub 2023 Mar 20. PMID: 36948055; PMCID: PMC10040689. IF 1.0, Online ISSN: 2210-2612.
Singh J, Benjamin M, Pandey AK, Kumari S, Ali MS, Palanichamy JK, Bakhshi S, Singh A, Pushpam D, Kumar A, Seth R, Singh I, Tanwar P, Singh AR, Sharma G, Arora M, Chopra A. Prognostic relevance of surface expression of cytokine receptor-like factor 2 in pediatric B-lineage acute lymphoblastic leukemia. Am J Cancer Res. 2023 Jun 15;13(6):2452-2470. PMID: 37424808; PMCID: PMC10326580.
Dubey H, Gupta S, Khan MA, Khurana S, Ranjan A*, Meena J, Ray MD, Tanwar P, Lakshmy R, Chopra A, Tiwari S. Evaluation of HE4 as a prognostic biomarker in uterine cervical cancer. Cancer Treat Res Commun. 2022 Dec 12;34:100672. doi: 10.1016/j.ctarc.2022.100672. Epub ahead of print. PMID: 36525756.
Dubey H, Goel H, Verma S, Gupta S, Tanwar K, Rahul E, Kapoor G, Vasantharaman J, Ranjan A*, Tanwar P, Chopra A. Clinicopathological and laboratory parameters of plasma cell leukemia among Indian population. Am J Blood Res. 2022;12(6):190-5. ISSN No 2160-1992.
Dubey H, Gupta S, Jha T, Tanwar K, Verma S, Ranjan A*, Tanwar P. Therapy related complications in plasmablastic lymphoma in immunocompetent individual. Am J Blood Res. 2022 Oct 15;12(5):168-171. PMID: 36419572; PMCID: PMC9677181.
Yadav A, Gokul G, Ranjan A, Gupta SK. Post-mortem CT: A useful tool to confirm a case of suspected sudden cardiac death. Cureus. 2022 Aug 15;14(8).
Kumari S, Ali MS, Singh J, Arora M, Verma D, Pandey AK, Benjamin M, Bakhshi S, Palanichamy JK, Sharma A, Singh I, Tanwar P, Singh AR, Pushpam D, Qamar I, Chopra A. Prognostic utility of key copy number alterations in T cell acute lymphoblastic leukemia. Hematol Oncol. 2022 Oct;40(4):577-587. doi: 10.1002/hon.3030. Epub 2022 Jun 4. PMID: 35644022.
Verma D, Kumar R, Ali S, Singh J, Arora M, Singh I, Kumari S, Bakhshi S, Sharma A, Palanichamy JK, Tanwar P. BAALC gene expression tells a serious patient outcome tale in NPM1-wild type/FLT3-ITD negative cytogenetically normal-acute myeloid leukemia in adults. Blood Cells, Molecules, and Diseases. 2022 Apr 8:102662. https://doi.org/10.1016/j.bcmd.2022.102662
Ray D, Ranjan A, Dubey H, De A, Kumar C. Ovarian Metastasis as Initial Presentation of Primary Thyroid Carcinoma: A Case Report and Review of Literature. Journal of Case Reports. 2020 Oct 3;10(3):192-6. http://dx.doi.org/10.17659/01.2020.0051

Dr. Ngangyola Thikhar

Details: Last Updated on Thursday, 10 September 2026 15:04

Dr. NGANGYOLA TUIKHAR

Dr. Ngangyola Tuikhar is a Scientist-I in the Department of Onco-Haematopathology, Dr. BRA-IRCH, AIIMS, New Delhi, where she has been working since October 2023. She completed her Ph.D. in Biotechnology in 2020 from the Institute of Bioresources and Sustainable Development (IBSD), Imphal.

Dr. Ngangyola Tuikhar has extensive research experience in microbiology, molecular biology, microbial genomics, metagenomics, flow cytometry, and bioinformatics, with hands-on experience in Next Generation Sequencing, Whole Genome Sequencing, Nanopore sequencing, and microbial genomic data analysis.

Dr. Ngangyola Tuikhar has contributed as a Quality Manager to the successful achievement of NABL accreditation for the department, supporting quality management, documentation, and compliance with laboratory accreditation requirements.

Area of Interests

Dr. Ngangyola Tuikhar research interests focus on developing targeted therapeutic strategies for Acute Myeloid Leukemia (AML) using CRISPR-based gene editing approaches to identify and validate novel molecular targets. Dr. Ngangyola Tuikhar is also interested in investigating TKI resistance in Chronic Myeloid Leukemia (CML), including resistance markers beyond known BCR::ABL1 kinase domain mutations. Future research will focus on integrating CRISPR-based functional studies, single-cell transcriptomics, and genomic approaches to identify leukemic stem cell-specific molecular drivers, mechanism and pathways associated with TKI resistance, with the aim of developing novel targeted therapeutic strategies for haematological malignancies.

Selected publications

Google Scholar

https://scholar.google.com/citations?hl=en&authuser=2&user=I5-yZugAAAAJ

Dr G. Smeeta

Details: Last Updated on Thursday, 10 September 2026 14:00

Dr G. Smeeta

Dr Smeeta Gajendra, MD, is Associate Professor in the Department of Onco-Haematopathology at Dr BRA Institute Rotary Cancer Hospital, All India Institute of Medical Sciences (AIIMS), New Delhi. She is a haematopathologist with over 15 years of experience in diagnostic haematopathology, haemato-oncology, flow cytometry, and molecular diagnostics.

Her clinical and academic work focuses on the integrated diagnosis and monitoring of haematological malignancies through the application of multiparametric flow cytometry, minimal/measurable residual disease (MRD) assessment, fluorescence in situ hybridization (FISH), and molecular diagnostics.

Dr Smeeta has contributed to the development and application of standardized flow-cytometry-based approaches for MRD detectionand disease monitoring. Her work includes research on leukemia stem cells in AML, MRD assessment in ALL, cytogenetic and molecular risk stratification in plasma cell neoplasms.

She has been actively involved in national and international academic forums, multidisciplinary research initiatives, faculty training programmes, and workshops in haematopathology and flow cytometry. She has also contributed to laboratory quality and accreditation initiatives in haemato-oncology diagnostics.

Significant Contributions

Advanced the application of multiparametric flow cytometry and MRD assessment for diagnosis, risk stratification, response evaluation, and disease monitoring in haematological malignancies.
Contributed to academic training and capacity building through workshops and educational programmes in MRD by flow cytometry, acute leukemia immunophenotyping, and CSF flow cytometry.
Contributed to laboratory quality and accreditation initiatives, including NABL preparedness and implementation of quality systems in haemato-oncology diagnostics.

Areas of Interest

MRD in Acute Leukemia, lymphoma and Multiple Myeloma
Acute Myeloid Leukemia and Leukemia Stem Cells
Molecular and Cytogenetic Diagnostics in Haematological Malignancies

Publications

Google Scholar:
https://scholar.google.com/citations?hl=en&user=cg5ocdsAAAAJ

Dr. Deepshi Thakral

Details: Last Updated on Thursday, 10 September 2026 15:03

Dr. Deepshi Thakral, PhD, Scientist II

Education and training

After completing B.Sc. (H) and M.Sc. in Biochemistry from the University of Delhi in 1997 and 1999, respectively, I pursued PhD in Biomedical Research from All India Institute of Medical Sciences, New Delhi. I was awarded the PhD degree in 2004 and went on to pursue postdoctoral training in Molecular Immunology at the Yale University School of Medicine, USA, one of the premier institutes for cutting-edge research in the field of Immunology (2005-2010). In 2011, I was appointed as a senior research associate (CSIR pool scheme) at All India Institute of Medical Sciences, New Delhi in the dept. of Pathology and continued as senior research officer in the dept. of transplant Immunology and Immunogenetics till mid-2017.

Research Experience

I have been actively involved in Biomedical research for more than two decades with expertise in molecular biology, immunology, and oncology. As a molecular immunologist, my primary research focus has been in understanding the human T cell biology in chronic diseases and developing immunotherapy modalities for cancer and infectious diseases. After my appointment as senior scientist in the Dept. of Onco-Haematopathology in June 2017, I have been involved in establishing both qualitative and quantitative molecular diagnostic and prognostic assays for hematologic malignancies. My ongoing research is focused on understanding the role of tumor microenvironment with special focus on stem cells and immune status in influencing the phenotypic and functional heterogeneity in haematological malignancies. We are using single cell transcriptomics to obtain a better understanding of Acute myeloid leukemia (AML) pathogenesis and chemo-resistance, especially the role of leukemic stem cells that contribute to high rate of relapse in AML. In parallel, another research focus is on the potential use of minimally invasive plasma-derived circulating tumor DNA (ctDNA) as a biomarker for real-time disease monitoring in AML. This may facilitate better prognostic risk stratification, options for targeted therapy, MRD assessment and relapse prediction in AML. Moreover, the genotype guided risk classification of AML with concurrent evaluation of immune phenotype in AML patients using cell free nucleic acids (ctDNA and circulating cell free RNA) is being investigated as a novel approach for disease monitoring that may facilitate the design of preclinical and early clinical studies of immunotherapeutic combinations for precision medicine in AML.

Achievements

I was awarded the third prize for best oral presentation at the 6^th annual congress of immuno-oncology organised by the Immuno-oncology society of India (I-OSICON2025, Bhubaneswar, Orissa). I won the best poster award at the 9th annual conference of Molecular Pathologist Association of India, Ahmedabad, Gujarat, 2022 and best oral presenter award at the 7th annual conference Molecular Pathologist Association of India at ACTREC, Mumbai, Maharashtra, 2019. I was selected as Senior research associate under the CSIR Pool Scientist Scheme (2010-2013). During my postdoctoral training, I had developed human CD8bb cell lines including the 2C murine hybridoma and the human H9 cell line co-expressing GFP and CD8bb homodimers that were licensed for generation of anti-Human CD8beta monoclonal antibody; the product is commercially sold by eBioscience (Clone: SIDI8BEE). This antibody detects the CD8 beta chain in both CD8αβ heterodimers and CD8ββ homodimers and has applications in flow cytometry, western blot, immunoprecipitation, and IHC. I was awarded the Trudeau Postdoctoral Fellowship from Yale University in 2006, and the Howard Hughes Undergraduate Science Education program fellowship for teaching (2006-2007). I had qualified National Eligibility Test from C.S.I.R. in 1999 and was recipient of several scholarships during B.Sc. and M.Sc. for obtaining top ranks.

Publications

https://pubmed.ncbi.nlm.nih.gov/?term=thakral+deepshi&sort=date

https://scholar.google.com/citations?hl=en&user=D-IRKxAAAAAJ

Dr. Pranay Tanwar

Details: Last Updated on Thursday, 10 September 2026 15:05

Dr. Pranay Tanwar, MBBS, MD, MNAMS, FIMSA

Dr. Pranay Tanwar is a physician-scientist and academic pathologist with over 20 years of experience in hematopathology, molecular pathology, cancer genomics, flow cytometry, translational oncology, and laboratory medicine.

Research & Academic Interests: Dr. Tanwar's research program focuses on integrating molecular and genomic approaches into cancer diagnosis, risk stratification, early detection, and therapeutic monitoring. His major areas of interest include:

Acute leukemia and myeloproliferative neoplasms: molecular biomarkers, risk stratification and clinically relevant genomic alterations.
Cancer genomics: whole-exome sequencing, transcriptomics, epigenomics and bioinformatics-based discovery of diagnostic and therapeutic biomarkers.
Gallbladder cancer: molecular biology, genomic profiling and development of approaches for early detection.
Breast cancer: genomics, therapeutic resistance and molecular characterization of triple-negative breast cancer.
HPV-associated malignancies: molecular detection and cancer screening, including oral, head and neck and cervical cancers.
Liquid biopsy and MRD: development of molecular approaches for disease surveillance and therapeutic monitoring.

Academic Contributions: Dr. Tanwar has authored approximately 120 peer reviewed publications, with an H-index of 21 and an i10-index of 55. He has also contributed to research mentorship, postgraduate and doctoral education, professional examinations, faculty recruitment boards, journal peer review, and academic editorial activities.

Honors & Recognitions: DST Young Scientist Fellowship Grant, PI of ICMR Task Force Grant of Breast cand Gall Bladder cancer, AIIMS Research Excellence Awards (2023 and 2024), Fellowship of the International Medical Science Academy, the Berend Houwen Travel Award, international contribution awards from the Korean Society of Haematology, and multiple scientific presentation awards.

Contact Us

All India Institute of Medical Sciences

Ansari Nagar, New Delhi - 110029

Board Number : +91-11-26588500 / 26588700

Fax : +91-11-26588663 / 26588641

Important Functionary

Chief Vigilance Officer(CVO), AIIMS, New Delhi

Important Links

Menu

Patient Care Services

Amar Ranjan Singh

Dr. Ngangyola Thikhar

Dr G. Smeeta

Dr. Deepshi Thakral

Dr. Pranay Tanwar

More Articles...

Contact Us

Important Links

Other AIIMS

Zo2 Framework Settings

Select one of sample color schemes

Google Font

Body

Header Wrapper

Menu Wrapper

Main Wrapper

Inset Wrapper

Bottom Wrapper

Footer Wrapper